Supernus to Host Third Quarter Results Earnings Conference Call

On October 27, 2020 Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, reported that the Company expects to report business results for the third quarter 2020 after 5:00 p.m. ET on Tuesday, November 3, 2020 (Press release, Supernus, OCT 27, 2020, View Source;2020.htm [SID1234569196]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jack Khattar, President and CEO and the executive management team will host a conference call to present the third quarter 2020 business and financial results on Wednesday, November 4, 2020 at 9:00 a.m. ET. Following management’s prepared analysis and discussion of business results, the call will be open for questions.
A live webcast will be available at www.supernus.com.

Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.
Conference dial-in: (877) 288-1043 International dial-in: (970) 315-0267 Conference ID: 1882244 Conference Call Name: Supernus Pharmaceuticals Third Quarter 2020 Earnings Conference Call

Following the live call, a replay will be available on the Company’s website under the ‘Investor Relations’ section. The webcast will be available on the Company’s website for 60 days following the live call.

TVM Capital Life Science Announces Substantially Oversubscribed US$478 Million Final Closing of TVM Life Science Innovation II, largest fund in the firm’s history

On October 27, 2020 TVM Capital Life Science, one of the leading life sciences venture capital firms in North America and Europe, reported the final closing of its latest fund, TVM Life Science Innovation II (TVM LSI II). Committed capital totals US$478 million which was raised from high profile international investors, including Eli Lilly and Company, other strategic investors, pension funds, endowments, foundations, fund-of-funds, wealth managers and large US banks as well as multi and single family offices from the Americas, Europe and South Korea (Press release, TVM Life Science Management, OCT 27, 2020, View Source [SID1234569175]). The geographical focus for the Fund’s investment activity is on North-America and Europe.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TVM LSI II was substantially oversubscribed. The Fund already sold its first investment in February 2020.

TVM LSI II will maintain TVM’s focus on investing in assets that provide a visible and attractive exit strategy from the outset with the goal of maximizing returns and providing early and significant liquidity for its investors. About 50-60% of the Fund’s capital is intended to be invested in "Project Focused Companies" ("PFCs") which are majority-owned by the Fund and set up for the development of early-stage drug candidates in a capital and time efficient manner. The remaining capital will be invested in late clinical stage biopharmaceutical companies as well as commercial stage medical device and diagnostic companies. The proven focus of TVM LSI II continues on building a portfolio of differentiated first-in-class and best-in-class assets that are diversified by indication and stage of development.

Dr. Luc Marengere, Managing Partner of TVM Capital Life Science commented: "We are thrilled by the strong support of existing and new investors in TVM LSI II. TVM LSI II is the largest fund raised by TVM since inception. In addition, we are grateful for the pivotal role in raising TVM LSI II in the Americas and Europe by New York based OCP and Founder Joelle Wyser-Pratte."

Stefan Fischer, Managing Partner (Finance) stated: "We are confident that TVM LSI II will not only continue the TVM success story for our investors but will also enable the financing of the development of new and differentiated treatment options for patients with significant unmet medical needs."

"The success of this fundraising effort is a strong validation of the innovative, capital-efficient investment strategy that we have implemented in 2012 together with Eli Lilly and Company. TVM LSI II intends to make investments in about 16 early-stage single asset PFCs and 10 late-stage companies with a focus on North America and Europe," wrote Dr. Hubert Birner, Managing Partner of TVM Capital Life Science based in Munich.

With the closing of TVM LSI II, Stefan Fischer was promoted to Managing Partner (Finance) and Dr. Sascha Berger was promoted to Partner.

In the past few months, the TVM investment team was complemented with the addition of Alexandra MacLean, MD and Alain Thibault, MD as Principals and, Dr. Valentina Agostina, Catello Somma and Philipp Lechner as Associates.

Centene Corporation Reports Third Quarter 2020 Results

On October 27, 2020 Centene Corporation (NYSE: CNC) reported its financial results for the third quarter ended September 30, 2020, reporting diluted earnings per share (EPS) of $0.97 and Adjusted diluted EPS of $1.26, including the risk corridor, charitable contribution commitment to the Company’s foundation and tax benefit highlighted below (Press release, Centene , OCT 27, 2020, View Source [SID1234569174]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In summary, the 2020 third quarter results were as follows

The third quarter results include the following items, which had a net benefit to GAAP and Adjusted diluted EPS of $0.29:

a pre-tax net benefit related to the Affordable Care Act (ACA) risk corridor receivable settlement of $398 million (net of minimum medical loss ratio payback and related expenses), or $0.52 per diluted share;
a pre-tax expense of $275 million, or $0.35 per diluted share, related to a charitable contribution commitment to the Company’s foundation; and
a favorable tax settlement of $72 million, or $0.12 per diluted share.
The third quarter net benefit of $0.17 per diluted share associated with the ACA risk corridor benefit and charitable contribution commitment to our foundation will be invested in enhanced growth and profitability initiatives for our Medicare and Health Insurance Marketplace businesses during the fourth quarter.

"We reported strong third quarter results with revenues up 53% as a result of the WellCare acquisition as well as product and geographic expansions, new programs and growth in many of our states," said Michael F. Neidorff, Chairman, President and Chief Executive Officer of Centene.

"As we benefited from the one-time risk corridor settlement this quarter, we’ve made the decision to reinvest the proceeds in the growth of our business as well as the communities in which we serve and live. Looking ahead, we expect our underlying businesses to continue to perform well in an uncertain environment and remain focused on executing our growth strategy across our diversified healthcare enterprise."

Third Quarter Highlights

September 30, 2020 managed care membership of 25.2 million, an increase of 9.9 million members, or 65%, over September 30, 2019.
Total revenues of $29.1 billion for the third quarter of 2020, representing 53% growth compared to the third quarter of 2019.
Health benefits ratio (HBR) of 86.4% for the third quarter of 2020, compared to 88.2% in the third quarter of 2019.
Selling, general and administrative (SG&A) expense ratio of 9.1% for the third quarter of 2020, compared to 8.9% for the third quarter of 2019.
Adjusted SG&A expense ratio of 8.9% for the third quarter of 2020, compared to 8.8% for the third quarter of 2019.
Diluted EPS for the third quarter of 2020 of $0.97, compared to $0.23 for the third quarter of 2019.
Adjusted diluted EPS for the third quarter of 2020 of $1.26, compared to $0.96 for the third quarter of 2019.
Operating cash flow of $(952) million for the third quarter of 2020, reflecting the payment of the health insurer fee and the 2019 risk adjustment liability, as expected. Cash flow provided by operations for the nine months ended September 30, 2020, was $2.5 billion, or 1.4 times net earnings.
Other Events

In October 2020, Centene issued $2.2 billion of 3.00% Senior Notes due 2030. The Company used the net proceeds of the notes, together with cash on hand, to redeem all of its outstanding 4.75% Senior Notes due 2022 and all of its outstanding 5.25% Senior Notes due 2025, including all premiums, accrued interest and expenses related to the redemptions.
In October 2020, Centene announced the expansion of its Medicare Advantage offerings for 2021. The Company’s Medicare plans expect to operate in 1,249 counties across 33 states in 2021, a 30% increase in counties over 2020.
In September 2020, Centene announced that it is expanding its offering in the 2021 Health Insurance Marketplace. Centene is expanding its Marketplace product, branded Ambetter, in nearly 400 new counties across 13 existing states. In addition, Ambetter-branded Marketplace products will be offered in two new states, Michigan and New Mexico. This brings the total number of states with Centene’s Marketplace offerings to 22.
In September 2020, Centene’s Illinois subsidiary, Meridian Health Plan of Illinois, Inc., expanded its Foster Care services through the YouthCare program.
In September 2020, Centene announced three executive leadership appointments to support the Company’s continued growth. Jonathan Dinesman was appointed to Executive Vice President, Government Relations; Shannon Bagley was appointed to Executive Vice President, Human Resources; and H. Robert Sanders was appointed to Executive Vice President, Human Resources.
In September 2020, Centene’s Oregon subsidiary, Trillium Community Health Plan, began operating under an expanded contract in three new counties, including the metro Portland area, and now serves as a coordinated care organization for six counties in the state.
In August 2020, Centene announced that its Indiana subsidiary, Managed Health Services, has been selected by the Indiana Department of Administration to continue serving Hoosier Care Connect members with Medicaid managed care and care coordination services.
Accreditations & Awards

In October 2020, Centene was named a 2020 Leading Disability Employer by the National Organization on Disability. This award recognizes companies that demonstrate exemplary employment practices for people with disabilities.
In September 2020, FORTUNE recognized Centene in its sixth-annual "Change the World" list of companies that have made an important social or environmental impact. Companies are recognized for innovative strategies that positively impact the world.
In August 2020, FORTUNE announced Centene’s position of #127 in its annual ranking of the world’s largest companies based on 2019 revenue, rising from #168 in the previous year’s annual ranking.
COVID-19 Pandemic

Beginning in March 2020, Centene announced a series of actions in support of various populations impacted by the COVID-19 pandemic. A detailed list of specific actions taken by the Company in response to the pandemic is shown on page 16 of this release.

Membership

The following table sets forth our membership by line of business:

Revenues

The following table sets forth supplemental revenue information ($ in millions):

Statement of Operations: Three Months Ended September 30, 2020

For the third quarter of 2020, total revenues increased 53% to $29.1 billion from $19.0 billion in the comparable period in 2019. The increase over the prior year was due to the acquisition of WellCare, growth in the Health Insurance Marketplace business, expansions, new programs and growth in many of our states, the reinstatement of the health insurer fee in 2020, and the ACA risk corridor receivable settlement, partially offset by the divestiture of our Illinois health plan.
HBR of 86.4% for the third quarter of 2020 represents a decrease from 88.2% in the comparable period in 2019. The decrease was attributable to the ACA risk corridor receivable settlement and the effect of the COVID-19 pandemic, partially offset by retroactive state premium rate adjustments and risk sharing mechanisms. The effect of the COVID-19 pandemic includes lower traditional medical utilization, partially offset by higher testing and treatment costs associated with COVID-19.
The SG&A expense ratio was 9.1% for the third quarter of 2020, compared to 8.9% in the third quarter of 2019. The Adjusted SG&A expense ratio was 8.9% for the third quarter of 2020, compared to 8.8% in the third quarter of 2019. The year-over-year increases to the ratios were due to the $275 million charitable contribution commitment to our foundation, partially offset by the addition of the WellCare business, which operates at a lower SG&A ratio, and the leveraging of expenses over higher revenues.
The effective tax rate was 26.8% for the third quarter of 2020, compared to 45.1% in the third quarter of 2019. The effective tax rate for the third quarter of 2020 reflects a favorable tax settlement, offset by the reinstatement of the health insurer fee in 2020. The effective tax rate for the third quarter of 2019 reflects the non-deductibility of a portion of our non-cash goodwill and intangible impairment, offset by the health insurer fee moratorium. For the third quarter of 2020, our effective tax rate on adjusted earnings was 26.1%.
Balance Sheet

At September 30, 2020, the Company had cash, investments and restricted deposits of $24.6 billion and maintained $1.1 billion of cash and cash equivalents held by unregulated entities. Medical claims liabilities totaled $12.9 billion. The Company’s days in claims payable was 52 days, which is an increase of one day over the second quarter of 2020. Total debt was $16.8 billion, which included $93 million of borrowings on our $2.0 billion revolving credit facility at quarter end. The debt to capitalization ratio was 39.1% at September 30, 2020, excluding $228 million of non-recourse debt. Our debt to capital ratio would have been 37.4% at September 30, 2020, when netting unregulated cash and cash equivalents with debt, and excluding non-recourse debt.

A reconciliation of the Company’s change in days in claims payable from the immediately preceding quarter-end is presented below:

Outlook

The Company’s annual adjusted diluted EPS guidance has been increased by $0.12 to reflect the favorable tax settlement recorded in the third quarter. The Company’s annual adjusted diluted EPS guidance reflects the third quarter net benefit of $0.17 per diluted share for the risk corridor and charitable contribution commitment to the Company’s foundation, offset by $0.17 per diluted share for growth and profitability initiative expenses associated with our Medicare and Marketplace businesses to be recorded in the fourth quarter.

Conference Call

As previously announced, the Company will host a conference call Tuesday, October 27, 2020, at approximately 8:30 AM (Eastern Time) to review the financial results for the third quarter ended September 30, 2020. Michael Neidorff and Jeffrey Schwaneke will host the conference call.

Investors and other interested parties are invited to listen to the conference call by dialing 1-877-883-0383 in the U.S. and Canada; +1-412-902-6506 from abroad, including the following Elite Entry Number: 0677783 to expedite caller registration; or via a live, audio webcast on the Company’s website at www.centene.com, under the Investors section.

A webcast replay will be available for on-demand listening shortly after the completion of the call for the next twelve months or until 11:59 PM (Eastern Time) on Tuesday, October 26, 2021, at the aforementioned URL. In addition, a digital audio playback will be available until 9:00 AM (Eastern Time) on Tuesday, November 3, 2020, by dialing 1-877-344-7529 in the U.S. and Canada, or +1-412-317-0088 from abroad, and entering access code 10147833.

Non-GAAP Financial Presentation

The Company is providing certain non-GAAP financial measures in this release as the Company believes that these figures are helpful in allowing investors to more accurately assess the ongoing nature of the Company’s operations and measure the Company’s performance more consistently across periods. The Company uses the presented non-GAAP financial measures internally to allow management to focus on period-to-period changes in the Company’s core business operations. Therefore, the Company believes that this information is meaningful in addition to the information contained in the GAAP presentation of financial information. The presentation of this additional non-GAAP financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP.

Specifically, the Company believes the presentation of non-GAAP financial information that excludes amortization of acquired intangible assets and acquisition related expenses, as well as other items, allows investors to develop a more meaningful understanding of the Company’s performance over time. The tables below provide reconciliations of non-GAAP items ($ in millions, except per share data):

To provide clarity on the way management defines certain key metrics and ratios, the Company is providing a description of how the metric or ratio is calculated as follows:

Health Benefits Ratio (HBR) (GAAP) = Medical costs divided by premium revenues.
SG&A Expense Ratio (GAAP) = Selling, general and administrative expenses divided by premium and service revenues.
Adjusted SG&A Expenses (non-GAAP) = Selling, general and administrative expenses, less acquisition related expenses.
Adjusted SG&A Expense Ratio (non-GAAP) = Adjusted selling, general and administrative expenses divided by premium and service revenues.
Adjusted Net Earnings (non-GAAP) = Net earnings less amortization of acquired intangible assets, less acquisition related expenses, as well as adjustments for other items, net of the income tax effect of the adjustments.
Adjusted Diluted EPS (non-GAAP) = Adjusted net earnings divided by weighted average common shares outstanding on a fully diluted basis.
Debt to Capitalization Ratio (GAAP) = Total debt, divided by total debt plus total stockholder’s equity.
Debt to Capitalization Ratio Excluding Non-Recourse Debt (non-GAAP) = Total debt less non-recourse debt, divided by total debt less non-recourse debt plus total stockholder’s equity.
Average Medical Claims Expense (GAAP) = Medical costs for the period, divided by number of days in such period. Average Medical Claims Expense is most often calculated for the quarterly reporting period.
Days in Claims Payable (GAAP) = Medical claims liabilities, divided by average medical claims expense. Days in Claims Payable is most often calculated for the quarterly reporting period.
In addition, the following terms are defined as follows:

State Directed Payments: Payments directed by a state that have minimal risk, but are administered as a premium adjustment. These payments are recorded as premium revenue and medical costs at close to a 100% HBR. The Company has little visibility to the timing of these payments until they are paid by a state.
Pass Through Payments: Non-risk supplemental payments from a state that the Company is required to pass through to designated contracted providers. These payments are recorded as premium tax revenue and premium tax expense.

Caris Life Sciences Raises $310 Million in Growth Capital from a Broad Syndicate of Leading Investors

On October 27, 2020 Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, reported that it has raised $310 million in growth capital (Press release, Caris Life Sciences, OCT 27, 2020, View Source [SID1234569172]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The financing includes $235 million in equity financing co-led by Highland Capital Management and Coatue, with participation from funds and accounts advised by T. Rowe Price Associates, Inc., OrbiMed, Millennium Management, Neuberger Berman, ClearBridge Investments, First Light Asset Management and other undisclosed investors.

The Company also raised $75 million in debt from Sixth Street as an extension to the $150 million in structured debt financing Sixth Street invested in September 2018. Sixth Street also participated in the equity round. Following the conclusion of this financing, Vijay Mohan, Co-founding Partner at Sixth Street, has been appointed to the board of directors.

Caris will dedicate the new capital to fund its continued growth in precision medicine to reinvent cancer care, accelerate innovative product development and pursue new initiatives in both the clinical trial and biopharmaceutical markets.

"Caris puts the patient at the center of everything we do, and focuses on fulfilling the promise of improving patient outcomes across all cancer types worldwide. As tumor profiling becomes standard practice, it’s important that we continue to grow rapidly as we maintain our leadership position," said David D. Halbert, Chairman and CEO of Caris Life Sciences. "We continue to advance our market-leading tumor profiling platform, clinical trial delivery service, grow our clinical and R&D laboratory facilities, expand our biopharmaceutical partnerships and further expand our investments in AI-powered innovation with our Precision Oncology Alliance collaborators. We are thrilled that our new partners share our vision to be the industry-leader in the precision medicine space."

"This financing represents the first significant external equity investment in Caris. We are tremendously proud to partner with a diverse and high-quality syndicate of leading investors with deep domain knowledge in healthcare and technology," said Brian J. Brille, Vice Chairman of Caris Life Sciences.

"We’ve reached an inflection point in the ability to use precision medicine to guide treatment decisions for cancer patients. Caris has built the leading clinically-focused comprehensive tumor profiling platform, providing the broadest coverage of actionable biomarkers, unparalleled physician support, and proprietary molecular signature analytics that will continue to enhance the utility of its testing platform for clinicians," said Nate Burns, Portfolio Manager and Head of Healthcare at Highland Capital Management. "The Company is also leveraging its unique multi-omics capabilities and extensive patient outcomes database to pursue compelling new pipeline opportunities including high-sensitivity liquid biopsy diagnostics and novel drug-target identification partnerships. We look forward to working with Caris and are excited about the tremendous growth opportunity ahead."

"By growing its platform, increasing its research and testing capacity, and strengthening its client partnerships, Caris has steadily advanced its position as the leading tumor profiling company," said Vijay Mohan, Co-founding Partner at Sixth Street. "We are proud to continue to support Mr. Halbert, Mr. Brille and the entire Caris team on their mission to help physicians and cancer patients make more personalized and precise treatment decisions. We look forward to our board engagement as Caris keeps leading as an innovator in precision medicine."

Compugen Presents New Research Data Further Supporting PVRIG as a Potentially Promising Target for Cancer Immunotherapy

On October 27, 2020 Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, reported the presentation of new research data further supporting PVRIG as a potentially promising target for cancer immunotherapy (Press release, Compugen, OCT 27, 2020, View Source [SID1234569169]). These data suggest that PVRIG inhibition may enhance T cell priming and infiltration into tumors and provide further evidence supporting the potential advantages of targeting PVRIG alone and in combination with TIGIT and PD-1 inhibitors, in tumors for which current checkpoint blockers have not proven successful. The new findings are delivered in a presentation at the 2020 TIGIT Therapies Digital Summit today, October 27, 2020, at 11:00 AM EDT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"There is a growing appreciation for the potential role of stem-like memory T cells, known as TSCM, in cancer biology, as these cells can self-renew and differentiate into effector cells that mediate direct anti-tumor effects. While recent evidence suggests that TSCM cells express TIGIT and PD-1, our work now shows that they also express PVRIG. Furthermore, our data show that PVRIG’s ligand, PVRL2, is expressed in both dendritic cells and tertiary lymphoid structures, as well as in PD-L1low less inflamed tumors," said Eran Ophir, Ph.D., Vice President of Research and Drug Discovery at Compugen. "These new data suggest that PVRIG may be involved in the inhibition of T cell proliferation, activation and infiltration into tumors and that its blockade by COM701, our first-in-class PVRIG inhibitor, may enhance T cell proliferation and infiltration into tumors through the modulation of these important cell populations, even in tumors in which current checkpoint blockers have not proven successful."

Anat Cohen-Dayag, Ph.D., President and CEO of Compugen, added, "We are excited to share this new data showing that PVRIG and PVRL2 are expressed in three cell types, TSCM cells, dendritic cells and tertiary lymphoid structures, all of which have been shown to be important in clinical response to checkpoint inhibitors. These data reinforce our view that PVRIG plays a significant role within the DNAM axis in triggering an immune response in the tumor microenvironment. As such, targeting the PVRIG pathway has the potential to provide new treatment options, as monotherapy or in combination with other immune checkpoints, for both inflamed and less inflamed tumors. Additionally, the co-expression of PVRIG, TIGIT and PD-1 on TSCM cells and their ligands on activated dendritic cells further substantiates our hypothesis that the simultaneous triple blockade of these pathways has the potential to expand the reach of cancer immunotherapies to new patient populations and cancer indications currently unresponsive or refractory to existing treatments."

Key new findings presented by Dr. Ophir in the presentation titled, "Rationalizing Combination Strategies to Maximize Clinical Response as Novel ICI Therapies Emerge," include:

PVRIG is expressed on stem-like memory T cells (TSCM), the cells that give rise to differentiated cytotoxic effector T cells, mediating direct anti-tumor effects in the tumor microenvironment.
PVRL2 and PVR, the ligands for PVRIG and TIGIT, respectively, are expressed in both PD-L1low and PD-L1high tumor types.
PVRL2 has abundant expression across various dendritic cell (DC) types; PVRL2, PVR and PD-L1 are expressed by activated DCs which are associated with efficient T cell activation.
PVRL2 is expressed in tertiary lymphoid structures, structures in the tumor bed where local T cell priming occurs and which have been shown to be linked to positive response to immunotherapy.
Cumulatively, the data presented suggest that COM701 blockade could potentially mediate an interaction between DCs & TSCM cells in the tumor bed and lymphoid organs. This potential mechanism could lead to increase T cell priming and infiltration into less inflamed tumors.